FocalTherics (NASDAQ:FOCL) SVP Steven Annen Acquires 5,000 Shares

FocalTherics (NASDAQ:FOCL) SVP Steven Annen purchased 5,000 shares of the stock in a transaction on Friday, August 14th. The stock was acquired at an average price of $4.75 per share, for a total transaction of $23,750.00. Following the completion of the purchase, the senior vice president directly owned 136,490 shares in the company, valued at approximately $648,327.50. The trade was a 3.80% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

FocalTherics Price Performance

FocalTherics stock opened at $4.36 on Tuesday. The firm has a market cap of $163.41 million, a P/E ratio of -4.23 and a beta of -0.04. The business’s 50-day simple moving average is $5.38. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34. FocalTherics has a one year low of $1.30 and a one year high of $6.40.

FocalTherics (NASDAQ:FOCL) last released its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. The company had revenue of $13.20 million during the quarter. As a group, sell-side analysts expect that FocalTherics will post -0.78 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Mizuho set a $15.00 target price on shares of FocalTherics and gave the stock an “outperform” rating in a report on Friday, July 17th. Wall Street Zen downgraded shares of FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of FocalTherics in a research note on Tuesday, June 2nd. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 target price on shares of FocalTherics in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, FocalTherics has a consensus rating of “Hold” and an average target price of $7.75.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Rock Springs Capital Management LP raised its stake in FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after acquiring an additional 91,500 shares during the period. Lido Advisors LLC bought a new position in FocalTherics during the first quarter worth $40,000. SmartHarvest Portfolios LLC acquired a new position in shares of FocalTherics in the first quarter valued at $38,000. Flax Pond Capital LLC acquired a new position in shares of FocalTherics in the fourth quarter valued at $2,623,000. Finally, Kovack Advisors Inc. bought a new position in shares of FocalTherics in the fourth quarter valued at about $53,000. 62.74% of the stock is owned by institutional investors and hedge funds.

FocalTherics News Roundup

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: Company insiders collectively purchased 116,000 shares at $4.75 per share, representing approximately $551,000 of open-market buying. The purchases included CEO Ryan Rhodes, CFO Kenneth S. Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and Directors Lance Willsey, Joshua Levine, Fran Schulz, and David R. Horn. The coordinated buying may suggest that management and directors view the recent weakness as an attractive entry point. FocalTherics insider transaction filing
• Positive Sentiment: Director Lance Willsey made the largest purchase, acquiring 50,000 shares for $237,500. CEO Ryan Rhodes also bought 21,000 shares for $99,750, while several other executives and directors increased their holdings by between 2.83% and 196.08%. FocalTherics director transaction filing
• Negative Sentiment: FocalTherics recently reported quarterly earnings of a $0.39-per-share loss, missing the consensus estimate for a $0.20 loss by $0.19. Revenue was $13.20 million, while the company posted a negative net margin of 56.26% and negative return on equity of 175.45%. Analysts expect a full-year loss of approximately $0.78 per share, which remains a key risk for the stock.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.